Navigation Links
Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
Date:1/26/2009

LA JOLLA, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) (www.transdelpharma.com), a specialty pharmaceutical company developing non-invasive, topically administered medications, announced today plans to expand its product development programs to include cosmetic/cosmeceutical products, which will utilize the Company's patented transdermal delivery system technology, TransdelTM. The Company has initiated discussions with potential sales and marketing partners for specific cosmetic/cosmeceutical products.

"We are very excited about entering into this new line of business and the expansion of our product portfolio for the Company," stated Dr. Juliet Singh, President and CEO. "The expansion into the cosmetic/cosmeceutical market may allow the Company to generate revenue during 2009."

The Company's patent for its Transdel(TM) technology specifically lists over 500 different drugs in over 60 therapeutic areas, including both approved and established drugs. Besides its lead drug, Ketotransdel(R) (a topical NSAID currently in a Phase 3 trial for acute pain), the Company is exploring potential co-development opportunities with corporate partners to expand its program into other therapeutic areas. The Transdel(TM) technology may also have an application to deliver drugs not listed in its patent, including novel drugs, and the company is seeking partnerships in this area as well.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP.OB) is a specialty pharmaceutical company developing non-invasive, topically- delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management, other therapeutic areas and for cosmeceutical products. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans" "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
2. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
3. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
4. Jackson & Coker Expands Emergency Medicine Staffing
5. QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President
6. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
7. HC Innovations Expands Management Team, Adding Vice President of Human Resources
8. Law Firm Freedland Russo Spearheads Record-Setting Whistleblower Case Against Pharmaceutical Giant Eli Lilly -- Firm Expands Offices to Include L.A. Entertainment Branch
9. Kendle Expands Asia/Pacific Operations with Opening of Additional Office in India
10. Wilson Sonsini Goodrich & Rosati Expands Consumer Regulatory Practice
11. PRA Expands Capabilities to Execute Multinational Trials in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... ... Schloz is still in shock after receiving a $2,500 Academic Award from California Casualty ... said. , She thinks the coming week is going to be a very joyful for ... help my students.” , The award will allow the 4th grade teacher at Tumwater Hill ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel Vitamins, a ... months-long rebranding effort. This includes the introduction of new packaging and messaging, as ... research, we learned that a simple, proactive approach to wellness is important to ...
(Date:3/27/2017)... ... 2017 , ... The homeowner improvement and repair market is expected to reach ... contractors for renovations is also on the rise. Per a 2017 report, 13% of ... 42% failed to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can ...
(Date:3/25/2017)... (PRWEB) , ... March 25, 2017 , ... Norland at Swissray is pleased ... analyzers for large subjects. The ELITE DXA has an active scan window, which is ... or long to fit in the scan area could not undergo an accurate total body ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 New England Pediatric Device Consortium ... award including funding and in-kind service towards the commercialization ... "Making blood draws less traumatic for children ... hospital experience better.  We,re looking forward to working with ... improve care for the kids we treat," said ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... ... worldwide markets for Dental Implants in US$ Million. The report provides separate ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period 2015 ...
Breaking Medicine Technology: